Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Retrieved on:
Monday, November 22, 2021
Patient, Greater, Cell, Breakthrough therapy, Company, Glycomimetic, AML, Cancer, Lymphatic system, CDE, Sel, Acute myeloid leukemia, Doctor of Philosophy, Blood, Prognosis, Survival rate, Center, Survival, Entrepreneurship, Center for Drug Evaluation and Research, Adult, Incidence, National Medical Products Administration, Bone marrow, CA, Immune system, NMPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry
"AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
Key Points:
- "AML is a highly aggressive hematological cancer, and the prognosis of patients with relapsed or refractory disease is extremely poor.
- This combined treatment approach could have a meaningful impact on the lives of patients living with relapsed or refractory AML."
- The Phase 3 trial with APL-106 is part of the overall development program for Apollomics in China that also includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.
- The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to uproleselan for the treatment of adults with relapsed or refractory acute myeloid leukemia.